Shares of major vaccine manufacturers fell in premarket trading following the announcement of Robert F. Kennedy Jr. as the prospective Secretary of Health and Human Services (HHS) under President-elect Donald Trump. Kennedy, known for his commitment to ending America’s chronic disease epidemic and skepticism of mass vaccinations, is causing panic among Big Pharma executives.
Prominent pharmaceutical corporations such as Moderna, Novavax, and BioNTech showed declines exceeding two percent in early trading in New York. Across the Atlantic, European companies like Sanofi and GSK experienced similar downward trends. Analysts attributed these declines to concerns over Kennedy’s potential to disrupt established ties between Big Pharma and government agencies. Kennedy has led initiatives questioning the integrity and effectiveness of federal agencies in vaccine oversight.
While there is now a Republican-majority Senate, speculation remains about Kennedy’s confirmation prospects. Some, like Rick Weissenstein of the TD Cowen investment banking corporation, believe he might not be confirmed, though a recess appointment could be possible.
Despite media hysteria over Kennedy’s vaccine skepticism, outlets such as POLITICO once touted the former Democrat possibly joining Barack Obama’s administration. In 2008, it was reported that his appointment to the Environmental Protection Agency (EPA) would please then-Senator Hillary Clinton, given his background as an environmental lawyer fighting for clean rivers and other improvements.
show less